Cite
HARVARD Citation
Pouwer, M. et al. (2017). Cardiovascular safety of BCR-ABL1 tyrosine kinase inhibitors: imatinib and ponatinib decrease plasma cholesterol and atherosclerosis in APOE3*Leiden.CETP Mice. Atherosclerosis. pp. e29-e30. [Online].